Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial



Summary

A phase 1/2 clinical trial investigated the safety and efficacy of GD2-targeting CAR T cells in children and young adults with high-risk neuroblastoma that relapsed or was refractory to standard treatments. The study, initially published, contained errors regarding patient enrollment, dosing, and toxicity. This correction clarifies that the study included a specific number of patients, details the correct dosing regimen of the CAR T cells, and accurately describes the observed toxicities related to the treatment. The efficacy results remain largely consistent, suggesting potential for GD2-CAR T cell therapy in this challenging patient population, though further research is needed.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!